Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Giulia Bianchi"'
Autor:
Arunava Chakravartty, Arnd Nusch, J. Thaddeus Beck, Juan Pablo Zarate, Seock-Ah Im, Dennis J. Slamon, Guy Jerusalem, Michelino De Laurentiis, Stephen Chia, Luis de la Cruz-Merino, Giulia Bianchi, Uday Deore, Gabe S. Sonke, Craig Wang, Peter A. Fasching, Patrick Neven, Tetiana Taran, Miguel Martin, Katarína Petráková
Publikováno v:
Journal of Clinical Oncology. 39:1001-1001
1001 Background: The Phase III MONALEESA-3 trial (NCT02422615) previously demonstrated a statistically significant improvement in OS with RIB, a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), plus FUL compared with placebo (PBO) plus FUL as first-l
Autor:
Federico Nichetti, Francesca Ligorio, Giulia Bianchi, Chiara Fabbroni, Filippo de Braud, Emma Zattarin, Licia Rivoltini, Giuseppe Capri, Riccardo Lobefaro, Claudio Vernieri
Publikováno v:
Journal of Clinical Oncology. 38:e13032-e13032
e13032 Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapies (ETs) are a mainstay of treatment for patients (pts) with hormone receptor-positive advanced breast cancer (HR+ aBC). Preclinical evidence indicates tha
Autor:
Stephen Chia, A. Thuerigen, Eva Ciruelos, Florence Lerebours, Giulia Bianchi, Dejan Juric, Nicholas C. Turner, Carolyn C. Nienstedt, Pamela Drullinsky, Manuel Ruiz Borrego, Antonia Ridolfi, Hope S. Rugo
Publikováno v:
Journal of Clinical Oncology. 37:1040-1040
1040 Background: In the phase 3 SOLAR-1 study, ALP + fulvestrant (FUL) improved PFS in pts with HR+, HER2– ABC with a PIK3CA mutation overall and in the small group of pts with prior cyclin-dependent kinase 4/6 inhibitor (CDKi) use. We report inter
Autor:
Gabriella Mariani, Giovanni Fucà, Giulia Bianchi, Paola Antonia Corsetto, Filippo de Braud, Giuseppe Capri, Monica Milano, Licia Rivoltini, Claudio Vernieri, Valter D. Longo
Publikováno v:
Journal of Clinical Oncology. 36:e14549-e14549
e14549Background: In preclinical studies, a plant-based, low-calorie, low-carbohydrate, low-protein diet, also known as fasting mimicking diet (FMD), has demonstrated anticancer activity that is me...
Autor:
Carolyn C. Nienstedt, Eva Ciruelos, Linnea I. Chap, Nikos Sophos, Stephen Chia, Chinjune Lin, Giulia Bianchi, William Jacot, Nicholas C. Turner, Dejan Juric, Ursa Brown-Glaberman, Manuel Ruiz Borrego, Hope S. Rugo, Antonia Ridolfi
Publikováno v:
Journal of Clinical Oncology. 36:TPS1107-TPS1107
TPS1107Background: Endocrine therapy (ET) is the standard of care for treatment of HR+, HER2– aBC. However, ET resistance occurs frequently due to dysregulation of the PI3K/AKT/mTOR pathway, specif...
Autor:
G. Moretti, Gaia Griguolo, Pierfranco Conte, T. Pascual, Giancarlo Bisagni, R. Vicini, Antonio Frassoldati, Carlo Alberto Giorgi, Enrico Orvieto, Matteo Curtarello, Maria Vittoria Dieci, Valentina Guarneri, Massimo Ambroggi, Gian Luca De Salvo, Giulia Bianchi, Laia Paré, Aleix Prat
Publikováno v:
Journal of Clinical Oncology. 36:507-507
507Background: Neoadjuvant trials with chemotherapy plus anti-HER2 agents consistently showed a lower rate of pathologic complete response (pCR) in HER2+/HR+ vs HER2+/HR-tumors. Here we report the ...
Autor:
José Baselga, Michael Stumm, Hope S. Rugo, Walter Jonat, Ernst Kubista, Humphrey Gardner, Heidi Lane, Penny Phillips, J Michael Dixon, Giulia Bianchi, Vladimir Semiglazov, Mario Campone, Betty Molloy, Jose I. Mayordomo, Jutta Steinseifer, Meritxell Bellet, Erika Tokaji, Richard Greil, Alexey Manikhas, Peter van Dam
Publikováno v:
Journal of Clinical Oncology. 27:2630-2637
Purpose Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance to endocrine therapy, and blockade of both pathways enhances antitumor activ
Autor:
Lucia Rinaldi, Claudia Maggi, Alessia Mennitto, Benvenuto Ferrari, Gabriella Mariani, Filippo de Braud, Roberta Mennitto, Barbara Re, Giuseppe Capri, Monica Milano, Giulia Bianchi, Claudio Vernieri, Claudia Stefanetti
Publikováno v:
Journal of Clinical Oncology. 35:e12556-e12556
e12556 Background: Safety and activity of weekly carboplatin plus paclitaxel in patients (pts) with metastatic breast cancer (mBC) are poorly known. Nevertheless, taxane-based chemotherapy (ChT) is the milestone in mBC treatment. In this retrospectiv
Autor:
Filippo de Braud, Giuseppe Capri, Paola Mariani, Gabriella Mariani, Matteo Duca, Giulia Bianchi, Ester Antelmi, Biagio Paolini, Daniele Giardiello, Luigi Mariani, Maria Luisa Carcangiu
Publikováno v:
Journal of Clinical Oncology. 34:e12053-e12053
e12053Background: Several studies on tumor samples taken from patients undergoing neoadjuvant chemotherapy (NAC) for triple negative (TN) breast cancer (BC) have demonstrated that presence and amount of tumor-infiltrating lymphocytes (TILs) are a pot
Autor:
Ling-Ming Tseng, Ana Lluch, Giulia Bianchi, Young Hyuck Im, Do-Youn Oh, Luca Gianni, Jose Luiz Pedrini, Tadeusz Pienkowski, Pinuccia Valagussa, Juan de la Haba-Rodriguez, Giampaolo Bianchini, Vladimir Semiglazov, Mei-Ching Liu, Brigitte Poirier
Publikováno v:
Journal of Clinical Oncology. 34:517-517
517Background: We investigated the treatment modulation of TIL, and its association with distant event free survival (DEFS) in patients (pts) with residual disease (RD) in the NeoSphere study Metho...